1-3 of 3
Xueyi Pan
Close
Sort by
Journal Articles

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

Qingqing Cai, Yi Xia, Panpan Liu, Yuchen Zhang, Huiqiang Huang, Yan Gao, Guowei Li, Xiuhua Sun, Xueyi Pan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9356–9357.
https://doi.org/10.1182/blood-2022-166237
Published: 2022
Journal Articles

Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Qingqing Cai, Panpan Liu, Yi Xia, Jun Cai, Huiqiang Huang, Zhiming Li, Hui Zhou, Yajun Li, Hanyu Wang, Ying Huang, Gao Yan, Xueyi Pan
Journal: Blood
Blood (2022) 140 (Supplement 1): 2299–2301.
https://doi.org/10.1182/blood-2022-168457
Published: 2022
Journal Articles

The Expression of Paks and Its Clinical Significance in T-Cell Lymphoblastic Lymphoma

Qingqing Cai, PhD, Ning Su, MM, Yu Fang, BMBS, Xu Chen, MDPhD, Xiaopeng Tian, MDPhD, Shuyun Ma, MM, Xiaoqin Chen, MDPhD, Zhongjun Xia, MDPhD, Tongyu Lin, MD PhD, Huiqiang Huang, MDPhD, Zhiming Li, MD PhD, Xueyi Pan, MDPhD, Yi Xia, MD PhD, Panpan Liu, MD PhD, Xuanye Zhang, MDPhD, Hang Yang, MD PhD, Stephen Yang Liang, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–16.
https://doi.org/10.1182/blood-2020-136975
Published: 2020